How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

738 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

481. Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

or history of cancer within the past 5 years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer. Related to laboratory findings: Positive test for hepatitis B surface antigen and/or hepatitis C antibody. Abnormal TSH level (TSH > ULN or < LLN). Positive urine pregnancy test. Related to previous or concomitant medications: Antidiabetic drugs other than insulin within 3 months prior to screening visit. Drugs affecting weight (e.g., sibutramine

2006 Clinical Trials

482. Use of a Portion Control Food Tool to Induce Weight Loss in Obese Type 2 Diabetics.

of the Diabetes Education Center in Calgary, AB, Canada, for at least 6 months prior to study enrollment Exclusion Criteria: taking a weight loss medication (sibutramine or orlistat) weight loss >10 lbs in 2 months preceding study enrolment consumption of dinner at restaurants more than twice weekly current diagnosis of cancer psychiatric illness under care of a psychiatrist surgery in the 3 months prior to the study, or expected during the study period history of bulimia or anorexia nervosa Contacts

2005 Clinical Trials

483. Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients

, or intervention. Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT00257257 Locations Layout table for location information United States, New Jersey Sanofi-Aventis Administrative

2005 Clinical Trials

484. Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity

intake.23 Second, unlike topiramate, zonisamide also modulates the function of serotonin and dopamine14, 15 --two neurotransmitters involved in the regulation of feeding behavior24 and the mechanisms of some medications with efficacy in either binge eating (SSRIs, d-fenfluramine) 25-29 or obesity (sibutramine, stimulants).30 Third, a broad range of antidepressants have been reported to reduce binge eating in both bulimia nervosa31 and binge eating disorder25-28,32 and preliminary observations suggest

2005 Clinical Trials

485. Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment

replacement therapy; Oral contraceptives; Antihypertensive agents; Metformin; Lipid-lowering agents; or Thyroid replacement therapy; Has been treated over the past 60 days, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications; All prescription or over-the-counter agents taken for the purpose of weight reduction, including (but not limited to) the following anti obesity agents: Prescription drugs such as orlistat (Xenical), sibutramine (Meridia

2007 Clinical Trials

486. ACTIV- Exercise Intervention in Healthy Young Men

of 1.5 h of aerobic exercise 3 times/ week Are willing to eat only foods provided by Pennington for the study period Exclusion Criteria: Abnormal resting or exercise ECG Significant renal, cardiac, liver, lung, or neurological disease (controlled hypertension is acceptable if baseline bp < 140/90 on medications) Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc Alcohol or other drug

2006 Clinical Trials

487. A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

sibutramine or phentermine in overweight and obese subjects. Condition or disease Intervention/treatment Phase Overweight Obesity Drug: pramlintide acetate Drug: sibutramine Drug: phentermine Drug: placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 258 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: A Randomized, Parallel (...) -Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects Study Start Date : November 2006 Actual Primary Completion Date : August 2007 Actual Study Completion Date : August 2007 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment

2006 Clinical Trials

488. "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

of other thiazolidinediones (rosiglitazone [AVANDIATM], pioglitazone [ACTOSTM]) Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc. Pregnancy Alcohol or other drug abuse Unwilling or unable to abstain from caffeine (48h) and tobacco (24h) prior to metabolic rate measurements Increased liver function tests at baseline (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper

2006 Clinical Trials

489. St. John's Wort for Tobacco Cessation

, venlafaxine, tryptophan and buspirone), MAO inhibitors, oral contraceptives, anti-cancer agents including imatinib and irinotecan, migraine medications (sumatriptan and zolmitriptan), methadone, lithium, sibutramine, atorvastatin and simvastatin, midazolam, alprazolam, fexofenadine, omeprazole, and general anesthetics (fentanyl, propofol, and sevoflurane); Have another household member or relative participating in the study; Have a known allergy to St. John?s Wort; Have a history of photosensitivity

2006 Clinical Trials

490. Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

of alcohol or other substance abuse, Hypersensitivity /intolerance to the active substance or to any of the excipients such as lactose, Administration of any investigational treatment (drug or device) within 30 days prior to screening, Previous participation in a Rimonabant study or previous administration of Rimonabant, Administration of any of the following within 3 months prior to screening visit: Anti obesity drugs (eg, sibutramine, orlistat), Other drugs for weight reduction (phentermine

2006 Clinical Trials

491. Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)

days prior to study entry. History of a medical or psychological condition or social circumstances that would impair the subject's ability to participate reliably in the study. Use within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat. (see Appendix 1 for detailed list

2006 Clinical Trials

492. Metformin Obesity Study

of insulin or insulin analogs; or any oral antidiabetic medication; acarbose, acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, metformin, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide or troglitazone. Prior use of drugs to aid in weight loss, including but not limited to: Benzphetamine Hcl, Diethylpropion Hcl, Fenfluramine Hcl, Phendimetrazine Tartrate, Phentermine Hcl, Orlistat, Sibutramine Hcl Monohydrate, Didrex, Tenuate, Pondimin, Bontril-SR, Adipex-P, Fastin

2005 Clinical Trials

493. Dairy Products and Metabolic Effects (Norwegian Part)

with Cyclosporin A. Change within the last 6 weeks before randomisation and during the study in the medications that could interfere with the lipid profile (i.e., anti- hypertensive drugs, oral corticosteroids, thyroid hormones, retinoids, thiazidic derivative, hormone replacement therapy). Treated with oral anticoagulants. Treated with protease inhibitors (indinavir, ritonavir, saquinavir) Treated against obesity: medical treatment within the last 6 weeks (orlistat, sibutramine) and/or surgery (gastroplasty

2005 Clinical Trials

494. Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

phase Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) Patient has any of the following

2004 Clinical Trials

495. A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression Condition or disease Intervention/treatment Phase Obesity Drug: CP-945,598 Drug: sibutramine Phase 2 Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 282 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment Official Title: A 6 (...) Call Center Pfizer More Information Go to Layout table for additonal information Identifier: Other Study ID Numbers: A5351013 First Posted: August 24, 2005 Last Update Posted: August 12, 2009 Last Verified: April 2006 Additional relevant MeSH terms: Layout table for MeSH terms Weight Loss Body Weight Changes Body Weight Signs and Symptoms Sibutramine Antidepressive Agents Psychotropic Drugs Appetite Depressants Anti-Obesity Agents

2005 Clinical Trials

496. Treatment Study of Frontotemporal Dementia

a stimulant (methylphenidate, dextroamphetamine, pemoline, or modafinil), or an antipsychotic medication, typical or atypical, including prochlorperazine and metoclopromide. Patients taking any of the following medications because of their potential interaction with dextroamphetamine: MAO use currently or within 14 days prior to start of study, Furazolidone, Guanethidine, norepinephrine, sibutramine, tricyclic antidepressants, carbonic anhydrase inhibitors. Patients taking the following medications

2004 Clinical Trials

497. A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION

agents Lipid-lowering agents Thyroid replacement therapy Antidepressant agents Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over-the-counter antiobesity agents Exclusion Criteria: Has been previously exposed to exenatide once weekly Has donated blood within 60 days of study start or is planning to donate blood during the study Currently being treated, or is expected to require or undergo treatment

2008 Clinical Trials

498. Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance

>1000 IU) on statin therapy. A history of generalized chronic pain such as fibromyalgia, or generalized arthritis. Any active cardiac problem including chest pain, angina, heart attack, bypass surgery, angioplasty/stent or unstable angina/acute coronary syndrome within the past 6 months. Taking other lipid lowering drugs including: ezetimibe, gemfibrozil, niacin, fibrates or bile acid sequestrants. Triglyceride level more than 400 mg/dl. Taking weight loss medication including orlistat, sibutramine

2008 Clinical Trials

499. The Effectiveness of Commercial Weight Loss Programmes

Taking lipid lowering or anti-hypertensive drugs History of obesity with known cause (i.e. Cushings disease, hypothyroidism) Previous gastric or weight loss surgery Taking any weight loss drug (including Orlistat or Sibutramine) Clinical depression Eating disorders Drug or alcohol abuse Any malabsorptive state (including lactose intolerance) Being treated for a malignancy Being pregnant Breastfeeding Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2006 Clinical Trials

500. Type 2 Diabetes in Children: A Growing Epidemic (Full text)

by logical treatments such as exercise and healthy eating habits for the child and family. However, these lifestyle changes are not always effective in controlling blood sugar. When lifestyle changes do not yield positive results, the clinician must decide which (if any) pharmacological treatments are safe to use in the pediatric population. Orlistat and sibutramine have been studied in children as treatments for obesity and appear to be safe and effective for this population. Metformin and insulin

2006 The Journal of Pediatric Pharmacology and Therapeutics : JPPT PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>